Ascendis Pharma Files October 2025 6-K Report
Ticker: ASND · Form: 6-K · Filed: Oct 15, 2025 · CIK: 1612042
| Field | Detail |
|---|---|
| Company | Ascendis Pharma A/S (ASND) |
| Form Type | 6-K |
| Filed Date | Oct 15, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $208.71 |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, sec-filing, foreign-private-issuer
Related Tickers: ASND
TL;DR
Ascendis Pharma (ASND) filed its October 6-K, standard reporting for foreign private issuers.
AI Summary
Ascendis Pharma A/S, a biopharmaceutical company, filed a Form 6-K on October 15, 2025. This report is for the month of October 2025 and is filed under the Securities Exchange Act of 1934. The company is incorporated in G7 and has its principal executive offices in Hellerup, Denmark.
Why It Matters
This filing provides routine updates for Ascendis Pharma A/S, a biopharmaceutical company, which is important for investors tracking the company's compliance and reporting obligations.
Risk Assessment
Risk Level: low — This filing is a routine report and does not contain significant new financial or operational information that would immediately impact the company's risk profile.
Key Players & Entities
- Ascendis Pharma A/S (company) — Registrant
- 001-36815 (company) — SEC File Number
- Tuborg Boulevard 12 DK-2900 Hellerup Denmark (company) — Principal executive offices
- October, 2025 (date) — Reporting period
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K is a report of a foreign private issuer pursuant to Section 13a-16 or 15d-16 under the Securities Exchange Act of 1934, for the month of October 2025.
What is Ascendis Pharma A/S's SEC file number?
Ascendis Pharma A/S's SEC file number is 001-36815.
Where are Ascendis Pharma A/S's principal executive offices located?
Ascendis Pharma A/S's principal executive offices are located at Tuborg Boulevard 12 DK-2900 Hellerup, Denmark.
Does Ascendis Pharma A/S file annual reports under Form 20-F or Form 40-F?
Ascendis Pharma A/S files annual reports under Form 20-F.
What is the SIC code for Ascendis Pharma A/S?
The Standard Industrial Classification (SIC) code for Ascendis Pharma A/S is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 515 words · 2 min read · ~2 pages · Grade level 15.8 · Accepted 2025-10-15 16:15:19
Key Financial Figures
- $208.71 — y and has an exercise price equal to US $208.71 per share, the closing price of the Ame
Filing Documents
- d884128d6k.htm (6-K) — 13KB
- d884128dex11.htm (EX-1.1) — 1201KB
- g884128dsp174.jpg (GRAPHIC) — 3KB
- g884128dsp175.jpg (GRAPHIC) — 3KB
- g884128dsp177.jpg (GRAPHIC) — 3KB
- g884128dsp178.jpg (GRAPHIC) — 3KB
- g884128dsp179.jpg (GRAPHIC) — 3KB
- g884128dsp180.jpg (GRAPHIC) — 5KB
- g884128dsp_24a.jpg (GRAPHIC) — 4KB
- g884128dsp_25a.jpg (GRAPHIC) — 8KB
- g884128dsp_25b.jpg (GRAPHIC) — 3KB
- g884128dsp_26a.jpg (GRAPHIC) — 6KB
- g884128dsp_33a.jpg (GRAPHIC) — 4KB
- g884128dsp_33b.jpg (GRAPHIC) — 8KB
- g884128dsp_34a.jpg (GRAPHIC) — 3KB
- g884128dsp_34b.jpg (GRAPHIC) — 6KB
- g884128page43.jpg (GRAPHIC) — 4KB
- g884128page44a.jpg (GRAPHIC) — 8KB
- g884128page44b.jpg (GRAPHIC) — 3KB
- g884128page45.jpg (GRAPHIC) — 6KB
- 0001193125-25-240272.txt ( ) — 1335KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Ascendis Pharma A/S Date: October 15, 2025 By: /s/ Michael Wolff Jensen Michael Wolff Jensen Executive Vice President, Chief Legal Officer